View by Specialty

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

Alzheimer's Disease/Cognition News

SPONSORED CONTENT
Save
SPONSORED CONTENT
December 06, 2023
4 min read
Save

Q&A: Falls Decision Rule aims to reduce unnecessary CT scans in overcrowded EDs

Q&A: Falls Decision Rule aims to reduce unnecessary CT scans in overcrowded EDs

A new clinical decision rule could help physicians determine which older ED patients who experienced a fall will require imaging, according to a study published in CMAJ.

SPONSORED CONTENT
December 06, 2023
1 min read
Save

Neighborhood disadvantage leads to poorer outcomes in those with focal epilepsy

Neighborhood disadvantage leads to poorer outcomes in those with focal epilepsy

ORLANDO — For a small cohort of individuals with focal epilepsy, “neighborhood disadvantage” was associated with poorer cognition including learning, memory and executive function, according to a poster.

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

SPONSORED CONTENT
December 01, 2023
1 min read
Save

Seizures associated with earlier decline to MCI in cognitively healthy adults

Seizures associated with earlier decline to MCI in cognitively healthy adults

ORLANDO — In cognitively healthy adults, the presence of seizures predicted earlier change from normal cognition to mild cognitive impairment but was not associated with change from MCI to dementia. according to research.

SPONSORED CONTENT
November 30, 2023
1 min read
Save

Phase 2 study of Alzheimer’s disease psychosis therapy initiated

Phase 2 study of Alzheimer’s disease psychosis therapy initiated

A phase 2 clinical trial has been initiated to evaluate the safety and efficacy of an inverse agonist for hallucinations and delusions associated with Alzheimer’s disease psychosis, according to the manufacturer.

SPONSORED CONTENT
November 29, 2023
1 min read
Save

FDA clears platform for non-invasive brain chemistry measurement

FDA clears platform for non-invasive brain chemistry measurement

The FDA has cleared the use of a magnetic resonance spectroscopy platform to provide non-invasive measurement of brain chemistry and support diagnostic processes for a range of brain-related illnesses.

SPONSORED CONTENT
November 29, 2023
2 min read
Save

Early-onset heart disease drives risk for Alzheimer's disease, other dementias

Early-onset heart disease drives risk for Alzheimer's disease, other dementias

Adults with a diagnosis of coronary heart disease before age 45 years are 36% more likely to develop dementia over 13 years of follow-up compared with those without a CHD diagnosis, data from the UK Biobank show.

SPONSORED CONTENT
November 28, 2023
2 min read
Save

Food insecurity associated with dementia risk

Food insecurity associated with dementia risk

Food insecurity was linked to an increased risk for dementia and faster memory decline among older adults, according to a study published in JAMA Network Open.

SPONSORED CONTENT
November 28, 2023
2 min read
Save

Visceral abdominal fat in midlife linked to Alzheimer’s disease

Visceral abdominal fat in midlife linked to Alzheimer’s disease

Having a higher amount of visceral abdominal fat in middle age was associated with an increased risk for developing Alzheimer’s disease, according to research presented at the annual meeting of the Radiological Society of North America.

SPONSORED CONTENT
November 27, 2023
1 min read
Save

First patient enrolled in phase 2b trial of novel therapy for mild Alzheimer’s

First patient enrolled in phase 2b trial of novel therapy for mild Alzheimer’s

The first patient has been enrolled in a European phase 2b clinical trial for AD04, a novel immunotherapy for the treatment of mild Alzheimer’s disease, according to the manufacturer.

SPONSORED CONTENT
November 20, 2023
1 min read
Save

Phase 3 clinical trial for investigational Alzheimer’s therapy expands to Asia, Europe

Phase 3 clinical trial for investigational Alzheimer’s therapy expands to Asia, Europe

A South Korea-based life sciences company has announced expansion into the European Union, United Kingdom, Korea and China of its phase 3 study of an oral, investigational PDE5 inhibitor to treat early Alzheimer’s disease.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails